Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sang-Qi Granula (also known as Sangqi Qingxuan formula) is a traditional Chinese medicine (TCM) herbal granule formulation developed by the China-Japan Friendship Hospital for the treatment of primary hypertension and associated vascular endothelial dysfunction. The formula is composed of eight medicinal herbs: Herba Taxilli, Fructus Lycii, Cortex Eucommiae, Semen Cassiae, Radix et Rhizoma Salviae Miltiorrhizae, Rhizoma Alismatis, Radix Puerariae Lobatae, and Flos Chrysanthemi indici. Sang-Qi Granula exerts its antihypertensive and cardioprotective effects by improving vascular endothelial function, reducing blood pressure, and preventing myocardial fibrosis. Mechanistically, it has been shown to suppress inflammatory responses by downregulating NF-κB and TGF-β signaling pathways while upregulating peroxisome proliferator-activated receptors alpha and gamma (PPARα and PPARγ).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sang-Qi Granula.